{"title":"Bronchoalveolar Lavage Lymphocytosis and Early Glucocorticoid Response: A Prospective Study of 150 Subjects With Interstitial Lung Disease.","authors":"Sahajal Dhooria, Harshith Rao, Nalini Gupta, Inderpaul Singh Sehgal, Ritesh Agarwal, Kuruswamy Thurai Prasad, Valliappan Muthu, Mandeep Garg, Amanjit Bal, Ashutosh Nath Aggarwal","doi":"10.1111/resp.70105","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>Bronchoalveolar lavage lymphocyte percentage (BLP) is considered a prognostic marker for interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF). Its association with an early glucocorticoid response (EGR) has not been studied systematically. We aimed to assess the association of BLP and other factors with EGR.</p><p><strong>Methods: </strong>We prospectively enrolled subjects with non-IPF ILDs and treated them with glucocorticoids. We defined EGR as a composite response in symptoms and pulmonary function tests 2 months after glucocorticoid initiation. Cases were those with EGR (responders), while non-responders (without EGR) formed the controls. The primary exposure was the BLP expressed on an ordinal scale: 0%-19%, 20%-29%, 30%-39%, ≥ 40%. Confounders included age, sex, body mass index, smoke exposure, %pred FVC, symptom duration, inflammatory and/or fibrotic phenotype on chest computed tomography. We also assessed factors associated with progressive disease at 6 months.</p><p><strong>Results: </strong>We included 150 subjects (mean age, 51.2 years; 39% men); 73% had either hypersensitivity pneumonitis or connective tissue disease-related ILD. One hundred and thirty-one subjects (69 responders; 62 non-responders) followed up at 2 months. The BLP (adjusted odds ratio [aOR], 1.64; 95% confidence intervals [CI], 1.03-2.63; p = 0.04) and symptom duration (aOR, 0.60; 95% CI, 0.40-0.92; p = 0.02) were independently associated with EGR. A BLP < 20% (aOR, 4.37; 95% CI, 1.37-13.96; p = 0.01) and history of smoke exposure (aOR, 4.59; 95% CI, 1.25-16.91; p = 0.02) independently predicted progressive disease at 6 months.</p><p><strong>Conclusion: </strong>Higher BLPs and shorter symptom duration were associated with EGR, while BLP < 20% and smoke exposure predicted progressive disease despite glucocorticoid treatment.</p>","PeriodicalId":21129,"journal":{"name":"Respirology","volume":" ","pages":""},"PeriodicalIF":6.3000,"publicationDate":"2025-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respirology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/resp.70105","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0
Abstract
Background and objective: Bronchoalveolar lavage lymphocyte percentage (BLP) is considered a prognostic marker for interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF). Its association with an early glucocorticoid response (EGR) has not been studied systematically. We aimed to assess the association of BLP and other factors with EGR.
Methods: We prospectively enrolled subjects with non-IPF ILDs and treated them with glucocorticoids. We defined EGR as a composite response in symptoms and pulmonary function tests 2 months after glucocorticoid initiation. Cases were those with EGR (responders), while non-responders (without EGR) formed the controls. The primary exposure was the BLP expressed on an ordinal scale: 0%-19%, 20%-29%, 30%-39%, ≥ 40%. Confounders included age, sex, body mass index, smoke exposure, %pred FVC, symptom duration, inflammatory and/or fibrotic phenotype on chest computed tomography. We also assessed factors associated with progressive disease at 6 months.
Results: We included 150 subjects (mean age, 51.2 years; 39% men); 73% had either hypersensitivity pneumonitis or connective tissue disease-related ILD. One hundred and thirty-one subjects (69 responders; 62 non-responders) followed up at 2 months. The BLP (adjusted odds ratio [aOR], 1.64; 95% confidence intervals [CI], 1.03-2.63; p = 0.04) and symptom duration (aOR, 0.60; 95% CI, 0.40-0.92; p = 0.02) were independently associated with EGR. A BLP < 20% (aOR, 4.37; 95% CI, 1.37-13.96; p = 0.01) and history of smoke exposure (aOR, 4.59; 95% CI, 1.25-16.91; p = 0.02) independently predicted progressive disease at 6 months.
Conclusion: Higher BLPs and shorter symptom duration were associated with EGR, while BLP < 20% and smoke exposure predicted progressive disease despite glucocorticoid treatment.
期刊介绍:
Respirology is a journal of international standing, publishing peer-reviewed articles of scientific excellence in clinical and clinically-relevant experimental respiratory biology and disease. Fields of research include immunology, intensive and critical care, epidemiology, cell and molecular biology, pathology, pharmacology, physiology, paediatric respiratory medicine, clinical trials, interventional pulmonology and thoracic surgery.
The Journal aims to encourage the international exchange of results and publishes papers in the following categories: Original Articles, Editorials, Reviews, and Correspondences.
Respirology is the preferred journal of the Thoracic Society of Australia and New Zealand, has been adopted as the preferred English journal of the Japanese Respiratory Society and the Taiwan Society of Pulmonary and Critical Care Medicine and is an official journal of the World Association for Bronchology and Interventional Pulmonology.